Peter Kolchinsky's videos and podcasts
February 2026
December 2025
PBMs: The Secretive Middlemen for Insurance and Drug Companies
No Patient Left Behind
BioCentury: KOLs call for updated Build Back Better to level playing field
No Patient Left Behind
Bucks County Herald: Drug price controls hurt investment in new medicines
No Patient Left Behind
New NPLB Video Illustrates Why Patients Deserve Better Math to Value New Drugs
No Patient Left Behind
The American Journal of Managed Care: Generalized Cost-Effectiveness Analysis to Assess Treatment Value in Hepatitis C
No Patient Left Behind
November 2025
Fairfax Connection: Our Neighborhood’s Special Role in Saving Babies from Norovirus</a>
No Patient Left Behind
Estimating a Drug’s Price After Loss of Exclusivity as a Function of Its Cost of Goods Sold
No Patient Left Behind
Journal of Comparative Effectiveness Research: Generalized cost–effectiveness analysis - charting a path forward for measuring the societal value of medical technologies
Do Cost-Effectiveness Analyses Account for Drug Genericization?
No Patient Left Behind
How We Cured Hepatitis C: 15 Years of Ingenuity, Investment, Risk, Failure, and Perseverance
No Patient Left Behind
The Evidence Base: New framework proposed for valuing medicines’ broader societal impact
No Patient Left Behind
New Paper: Leading Health Economists Explain How to Fix the Faulty & Outdated Models Used to Calculate the Value of Medicines
No Patient Left Behind
Beyond total revenues: How the IRA impacts investors’ early-stage R&D decision-making
No Patient Left Behind
NEW REPORT: Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices
No Patient Left Behind
The Well News: Ensuring Medicare Rx Price Negotiations Help Patients
No Patient Left Behind
October 2025
How does price setting at 9 years impact the NPV of a small molecule at time of launch?
No Patient Left Behind
R&D World: How much does the pharma industry spend on R&D anyway? Probably more than you thought
No Patient Left Behind
Comprehensive measurement of biopharmaceutical R&D investment
No Patient Left Behind
Older
Xtelligent Healthcare: The Importance of Accurately Measuring the Value of New Medications
No Patient Left Behind
USA Today: Mammograms can prevent breast cancer deaths. But many skip screening due to cost.
No Patient Left Behind